JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2020, Vol. 40 ›› Issue (08): 1131-1136.doi: 10.3969/j.issn.1674-8115.2020.08.022

• Review • Previous Articles     Next Articles

Effect of asymmetric dimethylarginine on development of atherosclerosis in patients with chronic kidney disease

CHEN Sheng-nan, SHEN Yan   

  1. Department of Nephrology, Kidney Hospital, the First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710061, China
  • Online:2020-08-28 Published:2020-08-28
  • Supported by:
    National Natural Science Foundation of China (81200541); Fundamental Research Fund for the Central Universities of China (1191329725); Key Research and Development of Shaanxi Province(2020KW-043); Project of Shaanxi Health and Family Planning Commission (2016D064); Xi'an Science and Technology Project (201805095YX3SF29); China Scholarship Fund (201506285033).

PDF (PC)

355

Abstract: Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor and is associated with the incidence of atherosclerosis (AS). ADMA is increased in patients with chronic kidney disease (CKD), which is a predictor of early endothelial dysfunction in CKD and a serologic marker of AS. ADMA can directly lead to or indirectly promote AS, and the concentration of ADMA in vivo is relatively stable, not being easily influenced by other factors. So the prediction value of ADMA for AS and its adverse events in CKD patients is extremely high. ADMA can not only be used for early detection of AS but also be used for reflecting the effectiveness of early intervention and patients' response to treatment by monitoring its dynamic changes, helping in understanding the progress and predicting the prognosis of the disease. This paper reviews the causes of the increase of ADMA and its role in promoting the development of AS in CKD patients.

Key words: asymmetric dimethylarginine, chronic kidney disease, atherosclerosis

CLC Number: